Alexion Requires Most Expensive Biotech Bid Since 2008

Alexion Requires Most Expensive Biotech Bid Since 2008

Gianluca Colla/Bloomberg

Though Roche’s own growth is projected to outpace some of its closest rivals, acquiring Alexion could fill a hole for the Swiss drugmaker.